Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025
NBIX(NASDAQ:NBIX) Additional Data from SAVITRI™ Study Expand on Top-Line Results Announced in April 2024 SAVITRI Poster Presentation Chosen as Finalist for Psych Congress Poster Awards SAN DIEGO, Sept. 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present...
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
NBIXSAN DIEGO, Aug. 26, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at four investor conferences in September. Chief Financial Officer Matt Abernethy, Chief Commercial Officer Eric Benevich, and Vice-President of Investor Relations Todd Tushla will...
Neurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
NBIXSAN DIEGO, Aug. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Canaccord Genuity 45th Annual Growth Conference at 8:00 a.m. ET on Wednesday, August 13, 2025. Chief Executive Officer Kyle Gano and Vice-President of Investor Relations Todd Tushla...
Analyst Expectations For Neurocrine Biosciences's Future
NBIXRBC Capital Reiterates Outperform on Neurocrine Biosciences, Maintains $145 Price Target
NBIXNeurocrine Biosciences Announces New Data From Phase 4 KINECT-PROTM Open-Label Study Showing Robust, Sustained Improvements In Physical, Social And Emotional Functioning In Patients With Tardive Dyskinesia Taking Once-Daily INGREZZA Capsules
NBIXNeurocrine Biosciences Announces New Data From Phase 2 Study Of Nbi-1117568 In Adults With Schizophrenia At American Society Of Clinical Psychopharmacology 2025
NBIXNeurocrine Biosciences To Present One-Year Data From Phase 3 CAHtalyst Pediatric Study At PES 2025, Showing Lasting Reductions In Glucocorticoid Doses Who Received CRENESSITY
NBIXNeurocrine Biosciences Presents New Phase 4 Analysis Showing INGREZZA Improves Function & Quality Of Life In Tardive Dyskinesia Patients
NBIXPresents New Data From The Phase 3 CAHtalyst Adult And Pediatric Studies Of CRENESSITY; Data Showed That A Substantial Proportion Of Pediatric Patients With Classic Congenital Adrenal Hyperplasia Achieved Physiologic-Range Glucocorticoid Doses And Normal
NBIXNeurocrine Biosciences Presents Study Showing Relationship Between Higher Glucocorticoid Dose And Adverse Clinical Outcomes
NBIXNeurocrine Biosciences Announces New Results From Phase 3 CAHtalyst Pediatric Study
NBIXNeurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target
NBIXNeurocrine stock gains as Q1 EPS beats estimates; Ingrezza sales climb 8% YoY with record new patients and strong analyst price target hikes.
Piper Sandler Reiterates Overweight on Neurocrine Biosciences, Lowers Price Target to $154
NBIXRBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $145
NBIXGuggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $165
NBIXBMO Capital Maintains Market Perform on Neurocrine Biosciences, Raises Price Target to $115
NBIXUBS Maintains Buy on Neurocrine Biosciences, Raises Price Target to $152
NBIXWhat 19 Analyst Ratings Have To Say About Neurocrine Biosciences
NBIXCanaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $160
NBIXNeedham Maintains Buy on Neurocrine Biosciences, Raises Price Target to $139
NBIXNeurocrine Biosciences Q1 Adj. EPS $0.70 Beats $0.54 Estimate, Sales $572.60M Beat $559.33M Estimate
NBIXWhat to Expect from Neurocrine Biosciences's Earnings
NBIXNeurocrine Biosciences Announces Initiation Of Phase 3 Registrational Program for NBI-1117568 As Potential Treatment For Adults With Schizophrenia
NBIXCanaccord Genuity Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $158
NBIXNeurocrine Announces Publication Of Post-Hoc Analysis From Two 48-Week Studies, KINECT 3 Extension And KINECT 4, Demonstrating Long-term Safety Profile And Robust Efficacy Of INGREZZA Capsules In Adults With TD In The Journal Of Clinical Psychiatry
NBIXEvercore ISI Group Maintains Outperform on Neurocrine Biosciences, Lowers Price Target to $185
NBIXHC Wainwright & Co. Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $168
NBIXNeurocrine Biosciences' Positive Crenessity Physician Survey Turns This Analyst Bullish
NBIXPhysician survey shows high uptake of Neurocrine Biosciences' Crenessity for patients with CAH.
What 16 Analyst Ratings Have To Say About Neurocrine Biosciences
NBIXNeedham Upgrades Neurocrine Biosciences to Buy, Announces $138 Price Target
NBIXRBC Capital Upgrades Neurocrine Biosciences to Outperform, Lowers Price Target to $137
NBIXUBS Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $137
NBIXDeep Dive Into Neurocrine Biosciences Stock: Analyst Perspectives (14 Ratings)
NBIXJP Morgan Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $184
NBIXNeurocrine Biosciences Presents New 48-Week Remission Data On Treatment Of Tardive Dyskinesia With INGREZZA Capsules
NBIXNeurocrine Biosciences Presents Data From KINECT-HD Study
NBIXMorgan Stanley Assumes Neurocrine Biosciences at Overweight, Lowers Price Target of $150
NBIXNeurocrine Biosciences Announces Initiation Of Phase 1 Study For NBI-1140675, A Second-Generation VMAT2 Inhibitor, In Healthy Adults For Neurological And Neuropsychiatric Conditions
NBIXNeurocrine Biosciences Reports Patient-Reported Outcome Data From The KINECT-PRO Study Of INGREZZA; Says 'Results showed significant and sustained improvements from baseline in all three patient-reported outcome measures,'
NBIXHC Wainwright & Co. Reiterates Buy on Neurocrine Biosciences, Maintains $185 Price Target
NBIXAssessing Neurocrine Biosciences: Insights From 15 Financial Analysts
NBIXHC Wainwright & Co. Reiterates Buy on Neurocrine Biosciences, Maintains $185 Price Target
NBIXNeurocrine Biosciences Authorizes $500M Share Repurchase Program; This New Share Repurchase Authorization Is In Addition To The $300M Accelerated Repurchase Program That Was Announced In October 2024 And Completed In Early February 2025
NBIXPiper Sandler Reiterates Overweight on Neurocrine Biosciences, Maintains $160 Price Target
NBIXBarclays Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $165
NBIXWhat Analysts Are Saying About Neurocrine Biosciences Stock
NBIXNeedham Reiterates Hold on Neurocrine Biosciencesto Hold
NBIXNeurocrine Biosciences Reveals New INGREZZA Data At Psych Congress 2024, Showing 60% Remission Rate For Tardive Dyskinesia After 48 Weeks In Long-Term Study
NBIXHC Wainwright & Co. Reiterates Buy on Neurocrine Biosciences, Maintains $190 Price Target
NBIX